Skip to contentE
Editas Medicine, Inc.
E
EDITEditas Medicine, Inc. Q1 2025 · 10-Q
Revenue$4.66M$4.66M+310.4% vs Q1 2024 Net Income-$76.09M-$76.09MN/M vs Q1 2024 EPS Diluted-$0.92-$0.92N/M vs Q1 2024 Operating Income-$76,163,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Editas Medicine, Inc. · CIK 1650664 · Engraved from SEC EDGAR
Free Cash Flowderived-$47,913,000N/M Margins · derivedOperating margin-1635.1%+4267.2 pt vs Q1 2024
Net margin-1633.5%+3824.7 pt vs Q1 2024
ended Mar 31, 2025 · filed May 12, 2025 · 42 d after period end